Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin …
AJ Moskowitz, G Shah, H Schöder… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine,
vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed …
vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed …
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression …
CH Moskowitz, A Nademanee, T Masszi, E Agura… - The Lancet, 2015 - thelancet.com
Background High-dose therapy followed by autologous stem-cell transplantation is standard
of care for patients with relapsed or primary refractory Hodgkin's lymphoma. Roughly 50% of …
of care for patients with relapsed or primary refractory Hodgkin's lymphoma. Roughly 50% of …
Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE
This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with
ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to …
ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to …
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies
TP Vassilakopoulos… - Therapeutic …, 2020 - journals.sagepub.com
The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has
improved considerably in recent years owing to the approval of highly active novel agents …
improved considerably in recent years owing to the approval of highly active novel agents …
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and …
AJ Moskowitz, H Schöder, J Yahalom, SJ McCall… - The lancet …, 2015 - thelancet.com
Background Pre-transplantation 18 F-fluorodeoxyglucose (FDG) PET-negativity is one of the
strongest predictors of outcome after high-dose therapy and autologous stem-cell transplant …
strongest predictors of outcome after high-dose therapy and autologous stem-cell transplant …
The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group
LS Constine, J Yahalom, AK Ng, DC Hodgson… - International Journal of …, 2018 - Elsevier
Relapsed and refractory Hodgkin lymphoma (HL) challenges clinicians to devise treatment
strategies that are effective and safe. This problem is particularly prominent in an era when …
strategies that are effective and safe. This problem is particularly prominent in an era when …
Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 …
LJ Bryan, C Casulo, PB Allen, SE Smith, H Savas… - JAMA …, 2023 - jamanetwork.com
Importance To our knowledge, this is the first clinical trial designed to investigate concurrent
treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or …
treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or …
[HTML][HTML] Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish …
R Garcia-Sanz, A Sureda, F de la Cruz, M Canales… - Annals of …, 2019 - Elsevier
Background In this work, we assessed the efficacy and safety of brentuximab vedotin (BV)
plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin …
plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin …
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
RW Merryman, RA Redd, T Nishihori, J Chavez… - Blood …, 2021 - ashpublications.org
Autologous stem cell transplantation (ASCT) can be curative for patients with
relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 …
relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 …
A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma
Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment
modality for relapsed/refractory Hodgkin lymphoma (HL). However, no large studies have …
modality for relapsed/refractory Hodgkin lymphoma (HL). However, no large studies have …